DNA PLASMID VACCINE IN ASYMPTOMATIC HIV

$25,114M01FY2000RRNIH

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications & trials

Paper 36890337 Paper 36599136 Paper 35843468 Paper 34973459 Paper 34743343 Paper 34355475 Paper 33990615 Paper 33840726 Paper 33002231 Paper 32936969 Paper 32860463 Paper 32655562 Paper 32146126 Paper 32139262 Paper 31943262 Paper 31864822 Paper 31505070 Paper 31404238 Paper 31082876 Paper 30974509 Paper 30549279 Paper 29599296 Paper 29563196 Paper 29523554 Paper 28581155 Paper 28408440 Paper 28275182 Paper 27917600 Paper 27465220 Paper 27208344 Paper 26831489 Paper 26821779 Paper 26684441 Paper 26390278 Paper 26241322 Paper 26112886 Paper 25071758 Paper 25010003 Paper 24473530 Paper 24457946 Paper 24158425 Paper 24000053 Paper 23395246 Paper 22474066 Paper 22348451 Paper 22340269 Paper 22300172 Paper 22025811 Paper 21885493 Paper 21732401 Paper 21226578 Paper 20971975 Paper 20887395 Paper 20874770 Paper 20825464 Paper 20718814 Paper 20681233 Paper 20418726 Paper 20138299 Paper 19858438 Paper 19832791 Paper 19631267 Paper 19422140 Paper 19398283 Paper 19247441 Paper 19194521 Paper 19193611 Paper 19176401 Paper 19150931 Paper 19092163 Paper 19090952 Paper 19059257 Paper 19026292 Paper 18988892 Paper 18949545 Paper 18938181 Paper 18788650 Paper 18715274 Paper 18652094 Paper 18617073 Paper 18597837 Paper 18549994 Paper 18549878 Paper 18537178 Paper 18460483 Paper 18447765 Paper 18436117 Paper 18384906 Paper 18365398 Paper 18347000 Paper 18337568 Paper 18323573 Paper 18248794 Paper 18215538 Paper 18212282 Paper 18155880 Paper 18098228 Paper 18049122 Paper 18035236 Paper 18033754

Abstract

A DNA based vaccine containing HIV-1 Env and Rev genes was tested for safety and host immune response in 15HIV-infected asymptomatic patients the CD4-positive lymphocyte counts >=500ul of blood and receiving no antiviral therapy. Successive groups of patients received t hree doses of vaccine at 30, 100, or 300-ug at 10-week intervals in a does-escalation trial. Some changes were noted in cytotoxic T-lymphocyte activity against gp 160-bearing targets. Importantly, enhanced specific lymphocyte proliferative activity against HIV-1 envelope was observed in multiple patients. Three of three patients in the 300-ug dose group also developed increased MIP-a levels which were detectable in their serum. Interestingly patients in the lowest dose group showed no overall changes in the immune parameters measured. The majority of patients who exhibited increased in any immune parameters were contained within the 300-ug, which was the highest dose group. These studies support further investigation of this technolgoy for the production of antigen-specific immune responses in humans.

View original record on NIH RePORTER →